Soft tissue sarcomas with complex genomic profiles

Virchows Archiv

Volumn 456, Issue 2, 2010, Pages 201-217

  Guillou, Louis ^a   Aurias, Alain ^b  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b INSTITUT CURIE   (France)

Author keywords

Genetics; Karyotype; Soft tissue sarcoma

Indexed keywords

AGE; ANGIOSARCOMA; CANCER MORPHOLOGY; CHONDROSARCOMA; CHROMOSOME ANALYSIS; CHROMOSOME LOSS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FIBROSARCOMA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC GAIN; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LEIOMYOSARCOMA; LIPOSARCOMA; METASTASIS; MYXOSARCOMA; NERVE SHEATH TUMOR; NONHUMAN; OSTEOSARCOMA; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION INDUCED NEOPLASM; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; STRUCTURE ANALYSIS; TUMOR DIFFERENTIATION; TUMOR GROWTH; GENETICS; KARYOTYPING; PATHOLOGY; SARCOMA;

DNA;

DNA, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; KARYOTYPING; PROGNOSIS; SARCOMA;

EID: 77950354811     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-009-0853-4     Document Type: Review

References (109)

1. Fletcher CDM, Unni KK, Mertens F (eds) (2002) World Health Organization classification of tumours. Pathology and genetics of tumors of soft tissue and bone. IARC Press, Lyon
2. Weiss SW, Goldblum JR (2008) In: Weiss SW, Goldblum JR (eds) Enzinger and Weiss's soft tissue tumors, 5th edn. Mosby- Elsevier, Philadelphia
3. Dei Tos AP (2006) Classification of pleomorphic sarcomas: where are we now? Histopathology 48:51-62
4. Sandberg AA (2005) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma. Cancer Genet Cytogenet 161:1-19
5. Mandahl N, Fletcher CDM, Dal Cin P et al (2000) Comparative cytogenetic study of spindle cell and pleomorphic leiomyosarcomas of soft tissues: a report from the CHAMP Study Group. Cancer Genet Cytogenet 116:66-73
6. Yang J, Du X, Chen K et al (2009) Genetic aberrations in soft tissue leiomyosarcoma. Cancer Lett 275:1-8
7. Fletcher CDM, Dal Cin P, De Wever I et al (1999) Correlation between clinicopathologic features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP Study Group. Am J Pathol 154:1841-1847
8. Wang R, Titley JC, Lu YJ et al (2003) Loss of 13q14-q21 and gain of 5p14-pter in the progression of leiomyosarcoma. Mod Pathol 16:778-785
9. Hu J, Rao UNM, Jasani S et al (2005) Loss of DNA copy number of 10q is associated with aggressive behavior of leiomyosarcomas: a comparative genomic hybridization study. Cancer Genet Cytogenet 161:20-27
10. Adamowicz M, Radlwimmer B, Rieker RJ et al (2006) Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas. Genes Chromosomes Cancer 45:829-838
11. Hernando E, Charytonowicz E, Dudas ME et al (2007) The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 13:748-753
12. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Med 10:594-601
13. Mita MM, Tolcher AW (2007) The role of mTOR inhibitors for treatment of sarcomas. Current Oncology Reports 9:316-322
14. Lee YF, John M, Falconer A et al (2004) A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res 64:7201-7204
15. Ren B, Yu YP, Jing L et al (2003) Gene expression analysis of human soft tissue leiomyosarcomas. Hum Pathol 34:549-558
16. Suehara Y, Kondo T, Fujii K et al (2006) Proteomic signatures corresponding to histological classification and grading of softtissue sarcomas. Proteomics 6:4402-4409
17. Kawaguchi K, Oda Y, Saito T et al (2003) Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decrease. J Pathol 201:487-495
18. Dei Tos AP, Maestro R, Doglioni C et al (1996) Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 148:1037-1045
19. Seidel C, Bartel F, Rastetter M et al (2005) Alterations of cancerrelated genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 114:442-447
20. Kawaguchi K, Oda Y, Saito T et al (2006) DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 19:106-114
21. Francis P, Namlos HM, Müller C et al (2007) Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8:73
22. Pérot G, Derré J, Coindre JM et al (2009) Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res 69:2269-2278
23. Deyrup AT, Lee VK, Hill CE et al (2006) Epstein-Barr virusassociated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol 30:75-82
24. Kubben FJGM, Kroon FP, Hogendoorn PCW et al (1997) Absence of Epstein-Barr virus in a gastrointestinal stromal cell tumour (GIST) in an adult human immunodeficiency virusseropositive patient with past Epstein-Barr virus (EBV) infection. Eur J Gastroent Hepatol 9:721-724
25. Moinfar F, Azodi M, Tavassoli FA (2007) Uterine sarcomas. Pathology 39:55-71
26. Quade BJ, Wang TY, Sornberger K et al (2004) Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 40:97-108
27. Miettinen M, Fetsch JF (2006) Evaluation of biological potential of smooth muscle tumours. Histopathology 48:97-105
28. Fletcher CD (1992) Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16:213-228
29. Fletcher CDM (2006) The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 48:3-12
30. Mertens F, Fletcher CDM, Dal Cin P et al (1998) Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Genes Chromosomes Cancer 22:16-25
31. Derré J, Lagacé R, Nicolas A et al (2001) Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest 81:211-215
32. Carneiro A, Francis P, Bendahl PO et al (2009) Indistinguishable genomic profiles and shared prognostic markers in undifferenti- ated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin? Lab Invest 89:668-675
33. Larramendy ML, Gentile M, Soloneski S et al (2008) Does comparative genomic hybridization reveal differences in DNA copy number sequence patterns between leiomyosarcoma and malignant fibrous histiocytoma? Cancer Genet Cytogenet 187:1-11
34. Kawai A, Kondo T, Suehara Y et al (2008) Global proteinexpression analysis of bone and soft tissue sarcomas. Clin Orthop Relat Res 466:2099-2106
35. Mairal A, Terrier P, Chibon F et al (1999) Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas: a comparative genomic hybridization analysis of a series of 30 cases. Cancer Genet Cytogenet 111:134-138
36. Chibon F, Mairal A, Fréneaux P et al (2000) The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma. Cancer Res 60:6339-6345
37. Nakayama R, Nemoto T, Takahashi H et al (2007) Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20:749-759
38. Shintani K, Matsumine A, Kusuzaki K et al (2006) Expression of hypoxia-inducible factor (HIF)-I alpha as a biomarker of outcome in soft tissue sarcomas. Virchows Arch 449:673-681
39. Hunter KW (2004) Ezrin, a key component in tumor metastasis. Trends Mol Med 10:201-204
40. Kim MS, Cho WH, Song WS et al (2007) Prognostic significance of ezrin expression in pleomorphic malignant fibrous histiocytoma. Anticancer Res 27:1171-1178
41. Weng WH, Ahlén J, Aström K et al (2005) Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clinical Cancer Res 11:6198-6204
42. Riggi N, Cironi L, Provero P et al (2005) Development of Ewing's sarcoma from bone-marrow-derived mesenchymal progenitor cells. Cancer Res 65:11459-11468
43. Riggi N, Cironi L, Provero P et al (2006) Expression of the FUSCHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 66:7016-7023
44. Matuschansky I, Hernando E, Socci ND et al (2007) Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 117:3248-3257
45. Fletcher CD, Gustafson P, Rydholm A et al (2001) Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 19:3045-3050
46. Deyrup AT, Haydon RC, Huo D et al (2003) Myoid differentiation and prognosis in adult pleomorphic sarcomas of the extremity: an analysis of 92 cases. Cancer 98:805-813
47. Bui Nguyen Binh M, Guillou L, Hostein I et al (2007) Dedifferentiated liposarcomas with divergent myosarcomatous differentiation developed in the internal trunk. A study of 27 cases and comparison to conventional dedifferentiated liposarcomas and leiomyosarcomas. Am J Surg Pathol 31:1557-1566
48. Montgomery E, Fisher C (2001) Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): a clinicopathological study. Histopathology 38:499-509
49. Fisher C (2004) Myofibrosarcoma. Virchows Arch 445:215-223
50. Merck C, Angervall L, Kindblom LG et al (1983) Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand Suppl 282:1-40
51. Mentzel T, Calonje E, Wadden C et al (1996) Myxofibrosarcoma: clinicopathologic analysis of 75 cases with emphasis on the low grade variant. Am J Surg Pathol 20:391-405
52. Huang HY, Lal P, Qin J et al (2004) Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 35:612-621
53. Lin CN, Chou SC, Li CF et al (2006) Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol 93:294-3043
54. Idbaih A, Coindre JM, Derré J et al (2005) Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. Lab Invest 85:176-181
55. Willems SM, Debiec-Rychter M, Szuhai K et al (2006) Local recurrence of myxofibrosarcoma is associated with increased in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 19:407-416
56. Willems SM, Mohseny AB, Balog C et al (2009) Cellular/ intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med 13:1291-1301
57. Nascimento AF, Bertoni F, Fletcher CDM (2007) Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases. Am J Surg Pathol 31:99-105
58. Gebhard S, Coindre JM, Michels JJ et al (2002) Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and followup analysis of 63 cases. A study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 26:601-616
59. Hornick JL, Bosenberg MW, Mentzel T et al (2004) Pleomorphic liposarcoma. Clinicopathologic analysis of 57 cases. Am J Surg Pathol 28:1257-1267
60. Miettinen M, Enzinger FM (1999) Epithelioid variant of pleomorphic liposarcoma: a study of 12 cases of a distinctive variant of high-grade liposarcoma. Mod Pathol 12:722-728
61. Sandberg AA (2004) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Liposarcoma. Cancer Genet Cytogenet 155:1-24
62. Schmidt H, Bartel F, Kappler M et al (2005) Gains of 13q are correlated with a poor prognosis in liposarcoma. Mod Pathol 18:638-644
63. Taylor BS, Barretina J, Socci ND et al (2008) Functional copynumber alterations in cancer. PLoS ONE 3:e3179
64. Rieker RJ, Joos S, Bartsch C et al (2002) Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas. Int J Cancer 99:68-73
65. Fritz B, Schubert F, Wrobel G et al (2002) Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 62:2993-2998
66. Singer S, Socci ND, Ambrosini G et al (2007) Gene expression profiling of liposarcoma identifies distinct biological types/ subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67:6626-6636
67. Matuschansky I, Hernando E, Socci NDet al (2008)A development model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 172:1069-1080
68. Dei Tos AP, Mentzel T, Fletcher CDM (1998) Primary liposarcoma of the skin: a rare neoplasm with unusual high grade features. Am J Dermatopathol 20:332-338
69. Furlong MA, Mentzel T, Fanburg-Smith JC (2001) Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol 14:595-603
70. Furlong MA, Fanburg-Smith JC (2001) Pleomorphic rhabdomyosarcoma in children: four cases in the pediatric age group. Ann Diagn Pathol 5:199-206
71. Little DJ, Ballo MT, Zagars GK et al (2002) Adult rhabdomyosarcoma. Outcome following multimodality treatment. Cancer 95:377-388
72. Parham DM, Ellison DA (2006) Rhabdomyosarcomas in adults and children. An update. Arch Pathol Lab Med 130:1454-1465
73. Li G, Ogose A, Kawashima H et al (2009) Cytogenetic and realtime quantitative reverse-transcriptase polymerase chain reaction analyses in pleomorphic rhabdomyosarcoma. Cancer Genet Cytogenet 192:1-9
74. Gordon A, McManus A, Anderson J et al (2003) Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3- FOXO1A fusion gene in one case. Cancer Genet Cytogenet 140:73-77
75. Scheithauer BW, Louis DN, Hunter S et al (2007) Malignant peripheral nerve sheath tumour (MPNST). In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) World Health Organization classification of tumours of the central nervous system. IARC, Lyon, pp 160-162
76. Mertens F, Dal Cin P, De Wever I et al (2000) Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP Study Group. J Pathol 190:31-38
77. Bridge RS, Bridge JA, Neff JR et al (2004) Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant Triton tumor: a cytogenetic and molecular cytogenetic study. J Clin Pathol 57:1172-1178
78. Kresse SH, Skarn M, Ohnstad HO et al (2008) DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. Mol Cancer 7:48
79. Storlazzi CT, Brekke HR, Mandahl N et al (2006) Identification of a novel amplicon at distal 17q containing the BIRC5/survivin gene in malignant peripheral nerve sheath tumours. J Pathol 209:492-500
80. Schmidt H, Würl P, Taubert H et al (1999) Genomic imbalances in 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer 25:205-211
81. Skotheim RI, Kallioniemi A, Bjerkhagen B et al (2003) Topoisomerase-II ? is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol 21:4586-4591
82. Schmidt H, Taubert H, Würl P et al (2001) Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 128:14-23
83. Mantripragada KK, Spurlock G, Kluwe L et al (2008) Highresolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clinical Cancer Res 14:1015-1024
84. Carroll SL, Stonecypher MS (2004) Tumor suppressor mutations and growth factor signalling in the pathogenesis of NF1- associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations. J Neuropathol Exp Neurol 63:1115-1123
85. Przygodzki RM, Finkelstein SD, Keohavong P et al (1997) Sporadic and thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in KRAS-2. Lab Invest 76:153-159
86. Naka N, Tomita Y, Nakanishi H et al (1997) Mutations of p53 tumor suppressor gene in angiosarcoma. Int J Cancer 71:952-955
87. Zietz C, Rossle M, Haas C et al (1998) MDM2 oncoprotein overexpression, p53 gene mutation, and VEGF upregulation in angiosarcomas. Am J Pathol 153:1425-1433
88. Domfeh AB, Fichera M, Hunt JL (2006) Allelic loss of 3 different tumor suppressor gene loci in benign and malignant endothelial tumors of the head and neck. Arch Pathol LabMed 130:1184-1187
89. Ahmad SA, Patel SR, Ballo MT et al (2002) Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol 20:521-527
90. Jensen ML, Schumacher B, Jensen OM et al (1998) Extraskeletal osteosarcomas. A clinicopathologic study of 25 cases. Am J Surg Pathol 22:588-594
91. Mertens F, Larramendy M, Gustavsson A et al (2000) Radiationassociated sarcomas are characterized by complex karyotypes with frequent rearrangements of chromosome arm 3p. Cancer Genet Cytogenet 116:89-96
92. Mohamed AN, Zalupski MM, Ryan JR et al (1997) Cytogenetic aberrations and DNA ploidy in soft tissue sarcoma. A southwest oncology group study. Cancer Genet Cytogenet 99:45-53
93. Lau CC, Harris CP, Lu XY et al (2004) Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39:11-21
94. Selvarajah S, Yoshimoto M, Ludkovski O et al (2008) Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res 122:5-15
95. Bayani J, Zielenska M, Pandita A et al (2003) Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 36:7-16
96. Bridge JA, Nelson M, McComb E et al (1997) Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 95:74-87
97. Sandberg AA, Bridge JA (2003) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Osteosarcoma and related tumors. Cancer Genet Cytogenet 145:1-30
98. Montgomery EA, Devaney KO, Giordano TJ et al (1998) Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed-Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin's disease, and various sarcomas. Mod Pathol 11:384-391
99. Meis-Kindblom JM, Kindblom LG (1998) Acral myxoinflammatory fibroblastic sarcoma: a low-grade tumor of the hands and feet. Am J Surg Pathol 22:911-924
100. Lambert I, Debiec-Rychter M, Guelinckx P et al (2001) Acral myxoinflammatory fibroblastic sarcoma with unique clonal chromosomal changes. Virchows Arch 438:509-512
101. Baumhoer D, Glatz K, Schulten H-J et al (2007) Myxoinflammatory fibroblastic sarcoma: investigations by comparative genomic hybridization of two cases and review of the literature. Virchows Arch 451:923-928
102. Mansoor A, Fidda N, Himoe E et al (2004) Myxoinflammatory fibroblastic sarcoma with complex supernumerary ring chromosomes composed of chromosome 3 segments. Cancer Genet Cytogenet 152:61-65
103. Hallor KH, Sciot R, Staaf J et al (2009) Two genetic pathways, t (1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J Pathol 217:716-727
104. Ida CM, Rolig KA, Hulshizer RL et al (2007) Myxoinflammatory fibroblastic sarcoma showing t(2;6)(q31;p21.3) as a sole cytogenetic abnormality. Cancer Genet Cytogenet 177:139-142
105. Laskin WB, Silverman TA, Enzinger FM (1998) Postradiation soft tissue sarcomas. An analysis of 53 cases. Cancer 62:2330-2340
106. Wiklund TA, Blomqvist CP, Raty J et al (1991) Postirradiation sarcoma. Analysis of a nationwide cancer registry material. Cancer 68:524-531
107. Lagrange JL, Ramaioli A, Chateau MC et al (2000) Sarcoma after radiation therapy: retrospective multi institutional study of 80 histologically confirmed cases. Radiation therapist and pathologist groups of the Federation Nationale des Centres de Lutte Contre le Cancer. Radiology 216:197-205
108. Inoue YZ, Frassica FJ, Sim FH et al (2000) Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue. J Surg Oncol 75:42-50
109. Nakanishi H, Tomita Y, Myoui A et al (1998) Mutation of the p53 gene in postradiation sarcoma. Lab Invest 78:727-733